Global Nasal
Drug Delivery Systems Market, by Dosage Form (Nasal Spray, Nasal Drops,
Nasal Gels, Nasal Powders, and Others), by Container Type (Non-pressurized Containers
and Pressurized Containers), by System Type (Multi-dose, Bi-dose, and Unit
Dose), by Therapeutics Application (Allergic and Non-allergic Rhinitis, Nasal
Congestion, Vaccination, and Others), by Distribution Channel (Hospitals
Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is
estimated to be valued at US$ 48.1 billion in 2018, and is projected to exhibit
a CAGR of 6.3% over the forecast period (2018 – 2026).
Novel drug delivery systems are
one of the fastest growing segment in the pharmaceutical industry. Nasal is a
transmucosal drug delivery system, used to administer drug through nasal
cavity. Numerous studies are conducted to study the systemic bioavailability of
drug and on nasal administration of vaccine, peptide and hormonal therapy, and
other drugs which are usually delivered by parenteral route.
Growth in nasal drug delivery
system market is attributed to high advantages of nasal administration and
increasing innovative nasal drug delivery systems. Moreover, expanding
therapeutic application is expected to drive growth of the nasal drug delivery
systems market. For instance, number of pharmaceutical and biopharmaceutical
companies are adopting nasal drug delivery system for the treatment of acute
migraine, pain management, Alzheimer disease etc.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1944
For instance, in 2016, Lannett
Company, Inc. received Abbreviated New Drug Application (ANDA) approval from
the U.S. FDA for its Sumatriptan Nasal Spray intended for the treatment of
migraine. Moreover, in June 2018, Impax Specialty Pharma, Inc., a specialty
pharmaceutical company, received US FDA approval for Zomig Nasal Spray to treat
acute migraine in patients aged 12 years and above.
Furthermore, in 2017, FDA
approved OptiNose U.S. Inc.’s Xhance, which is a novel combination of drug and
device to deliver fluticasone propionate to treat nasal polyps. Such product
launches with diverse therapeutic application are augmenting the nasal drug
delivery systems market growth.
Browse Market Data 40 Tables and
38 Figures spread through 180 Pages and in-depth TOC on "Nasal Drug
Delivery Systems Market, by Dosage Form (Nasal Spray, Nasal Drops, Nasal Gels,
Nasal Powders, and Others), by Container Type (Non-pressurized Containers and
Pressurized Containers), by System Type (Multi Dose, Bi Dose, and Unit Dose),
by Therapeutics Application (Allergic and Non-allergic Rhinitis, Nasal
Congestion, Vaccination, and Others), by End User (Hospitals and Home Care
Settings) and by Region - Global Forecast to 2026”
Market players in nasal drug
delivery systems are focusing on inorganic strategies, in turn consolidating
the market. For instance, in 2014, Endo International plc, acquired Natesto,
the first and only testosterone nasal gel till that date, from Trimel BioPharma
SRL, used for the treatment of hypogonadism via replacement therapy.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/nasal-drug-delivery-systems-market-1944
Furthermore, in 2015, Eli Lilly
and Company acquired Locemia's intranasal glucagon, which was in phase III
clinical testing for the treatment of hypoglycemia. Such product acquisition is
expected to strengthen the company’s product portfolio, in turn strengthening
the market share of the acquirer.
Key takeaways of the Nasal Drug
Delivery Systems Market:
The global nasal drug delivery
systems market is expected to expand at a CAGR of 6.3% during the forecast
period (2018 – 2026), owing to increasing approvals for nasal drug delivery
systems
Nasal spray segment is expected
to be dominant, owing to large number of products offered in this segment and
increasing research to launch new products in this segment
Some of the major players
involved in global nasal drug delivery systems market include Merck & Co.,
GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc.,
Baxter International, Inc., Valeant Pharmaceuticals International, Inc.,
Becton, Dickinson and Company, and Novartis AG
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1944
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment